About

Bio-Neuroscience convenes an outstanding mix of innovators, CEOs and decision-makers in CNS neuroscience drug development from the leading biotech companies, investors and pharma companies in the sector

Insight - Access - Engagement - Impact

Premier Gathering of Innovators

The one event which convenes a high-level, by-invitation, boutique gathering of thought leaders, innovators, CEOs and senior decision-makers from the leading stakeholders groups in CNS neuroscience drug development.

The business of CNS Neuroscience drug development.

Where CEOs and C-level executives of the hottest companies come together with industry leaders, decision-makers, patient organizations, funders and the leading investors in CNS neuroscience drug development to dive into the the issues that matter most to stakeholders.

Elevating Engagement and Collaboration

A unique level of sustained high-quality discussion, access, engagement and partnering in a truly unique and ideally curated event.

Broadreach Neuro Summits - Participant Comments

Speaking at Bio-Neuroscience was a great experience, as I had the opportunity to share insights with a select group of peers who are passionate about neuroscience advancement. The engaging discussions combined with the interactive discussions during the breaks underscored the value of the meeting.

Craig Thompson

CEO - Cerevance

Great memories from Amsterdam Bio-Neuroscience 2024! A great boutique event and the place to be for anyone with interests in translational neuroscience. Well-balanced list of selected attendees, great in-depth discussions and plenty of time for networking. The 2025 edition is getting closer and closer, looking forward to attending again.

José L. Lanciego MD, PhD

Chair - International Brain Research Organization Pan-European Committee
Senior Scientist, CNS Gene Therapy Program
Functional Neuroanatomy of the Basal Ganglia Lab, CIMA

Vision

Convening the full value chain to disrupt silos and curate highly interactive, multi-disciplinary, cross-industry, and multi-stakeholder discussions of opportunities, challenges, hurdles and ways forward.

Drive transformational connections, discussion and partnering for startups and growth companies.

Deliver insight, access, engagement and partnering to foster innovation and accelerate value creation.

Contribute to meaningful improvement in healthcare outcomes and positive impact for patients and society.

Get feedback and advice on your business, your objectives and your core challenges from leading innovators, investors and industry leaders in CNS neuroscience drug development.

Why Now?

Now is the time for CNS neuroscience drug development. We have entered a time when truly rational drug discovery and development is possible and where new discoveries, tools, technologies, biomarkers and insights enable improved development.

Investor and industry interest is booming, yet key challenges remain that can only be addressed by bringing together the leading translational research, clinicians, entrepreneurs, CEOs, CSOs and CMOs from the leading biotech companies, with relevant therapeutic area and business development heads from big pharma and large biotech, as well as the Partners and Directors heading neuroscience investment at the most active and important investment funds.

The 2024 pilot edition established Bio-Neuroscience as a unique, high-level and interactive summit providing participants exceptional value in terms of the experience, insight, access and impact.

Agenda & Program - 2025 Edition

Day 0 - February 25

15:00 - Registration & Networking Coffee

16:00 - Program Opens

18:00 - Welcome Reception

Day I - February 26

08:15 - Registration Opens

09:00 - Start of Program

13:15 - Networking Lunch

17:45 - End of Day & Networking Reception

Day II - February 27

08:15 - Registration Opens

09:00 - Start of Program

12:45 - Networking Lunch

16:15 - End of Day & Networking Reception

Program

shutterstock_128316104 Thinking Impulses copy.jpg

Meet our Advisory Board

Advisory Board - 2026

Stacie Weninger

Executive Director - F-Prime Biomedical Research Initiative

Husseini K Manji, MD, FRCPC

Professor - Oxford University, Co-chair - UK Government Mental Health Mission

Kees Been

Chief Executive Officer - Kynexis Therapeutics Inc.

Arno de Wilde

Managing Director - EQT Life Sciences

Robert Thorne

Denali Fellow - Denali Therapeutics
Adjunct Associate Professor - University of Minnesota
President - International Brain Barriers Society (IBBS)

Claire Leurent

Managing Director - AbbVie Ventures

Andrea Soto Padilla

Business Development - Amsterdam UMC

Pieter van Bokhoven

Chief Scientific Officer - IXA Amsterdam Neuroscience UMC

Philip Scheltens

Head, Dementia Fund, Partner - EQT Life Sciences

Hakan Goker

Managing Director, Head of Healthcare & Life Sciences - M-Ventures

Juan Carlos Lopez

Managing Director - Haystack Science, formerly Chief Editor - Nature Medicine & Founding Editor - Nature Reviews Neuroscience

Sourav Kole

Investor & Board Member - Independent

Rita Balice-Gordon

Chief Executive Officer - Muna Therapeutics

Bruce Leuchter

President & CEO - Neurvati Neurosciences

Martien Kas

President - European College of NeuroPsychopharmacology (ECNP)

Advisory Board

Meet the Speakers - 2025 Edition.
The 2026 speaker line up will be announced soon!

Proudly convening leading speakers and stakeholders from across the sector

Steve Brannan

FIRESIDE CHAT - Former Chief Medical Officer - Karuna Therapeutics

Pablo Sardi

Global Head, Rare & Neurologic Diseases Therapeutic Area - Sanofi

Hugh Nuthall

Executive Director, Search & Evaluation, Neuroscience - Eli Lilly

Yael Weiss

CEO - Mahzi Therapeutics

Brigit de Jong

Neurologist - Amsterdam University Medical Center

Vikas Sharma

Chief Business Officer - QurAlis

Tushar Satav

CEO - Keystonemab B.V.

Yann Gaston-Mathé

Co-Founder & CEO - Iktos

Tarek Samad

Senior Vice President & Global Head of Research - Lundbeck

Jan Klatt

Senior Vice President, Head of the Development Unit Neurology & Immunology - Merck KGaA

Sander van Deventer

Co-Founder & President of R&D - VectorY Therapeutics

Nawal Roy

Founder & CEO - Holmusk

Leonard van den Berg

Chair - TRICALS, Founder & Chair - ENCALS, Founder & Director - ALS Centrum Nederland

Charlene Son Rigby

President & Founding Member - STXBP1 Foundation, & CEO - Global Genes

John Nieland

Co-Founder & CSO - 2N Pharma

Claire Leurent

Managing Director - AbbVie Ventures

Philip Scheltens

Head, Dementia Fund, Partner - EQT Life Sciences

Raúl Martín-Ruiz

Partner - Ysios Capital

Steven Biesmans

Principal - UCB Ventures

Sunitha Malepati

Founder - Buffalo Initiative, Vice President - CACNA1A Foundation

Frédéric Destrébecq

Executive Director - European Brain Council (EBC) & European Brain Foundation (EBF)

Anela Vukoja

COO - Apollo Health Ventures

Robert Thorne

KEYNOTE SPEAKER - Denali Fellow - Denali Therapeutics
Adjunct Associate Professor - University of Minnesota
President - International Brain Barriers Society (IBBS)

Allyson Berent

Chief Scientific Officer - Foundation for Angelman Syndrome Therapeutics (FAST)

Thomas Michael Thestrup

Senior Principal - Angelini Ventures

Klaus Dugi

CEO - Vandria SA

Alexander Natz

Secretary General - European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)

Thomas M. Kaiser

Chief Scientific Officer - Avicenna Biosciences, Inc.

Keno Gutierrez

General Partner - BioGeneration Ventures (BGV)

Husseini K Manji, MD, FRCPC

KEYNOTE SPEAKER - Professor - Oxford University, Co-chair - UK Government Mental Health Mission

Jacopo Andreose

CEO - Angelini Pharma S.p.A.

Clara Campàs

Managing Partner & Co-Founder - Asabys Partners

Stevin Zorn

President & CEO - MindImmune Therapeutics

Bruce Leuchter

President & CEO - Neurvati Neurosciences

Francesca Cormack

Chief Scientist - Cambridge Cognition

Kenneth Maiese, MD

Chief Scientific Officer, Neurology - Danaher Diagnostics

Present

Presenting Companies

Benefit From

Pre-summit guidance and feedback on your deck.

A pre-summit dry-run presentation with feedback.

5 minute presentation followed by 5 minutes Q&A with an expert panel of relevant investors and industry: In front of the full audience in the plenary session - not off in some side room!

Join a curated selection of the most innovative, promising and high potential companies with potential to transform CNS neuroscience drug development & treatment. Selection is by excellence and potential, not by price tag! There is no cost to present beyond the regular startup or private company registration fees.

2026 Applications Open on 1 July 2025.

Your Poster in the networking area.

Post Pitch Meeting space in the main networking area to facilitate additional discussion in the networking break immediately following your session.

Over 2 Days of sustained engagement with the best network of innovators, investors, industry leaders & decision-makers in CNS neuroscience drug development.

Option to add an exclusive company exhibition stand. There is no requirement to sponsor or exhibit; these exist as separate options each and provide exceptional target market visibility with key investors, industry leaders and stakeholders. For avoidance of any confusion, exhibiting has no impact on selection for presentation.

Apply or Nominate to Pitch

Who will you meet?

Over 2 days of high-level interactive discussion, networking and partnering with:

Industry Leaders

Industry decison-makers, Heads of Therapeutic Area, Scouting, Alliance Management, Business Development & Licensing, Strategy & Portfolio from pharma & large biotech.

Key Opinion Leaders

Key Opinion Leaders from research, clinical development & care, strategy, finance, business development, licensing, regulatory, market launch & M&A.

Founders & CEOs

Founders, CEOs & C-Level from the most innovative and hottest CNS neuroscience companies leading innovation & deals in the sector.

Government & NGOs

Public funding bodies, policy makers, public agencies, societies, associations & NGOs in neuroscience, agencies, regulatory bodies.

Investors

Managing Partners & Partners from the most active CNS Neuroscience investing VC funds, Managing Directors & Directors of the leading Corporate Venture, Private Equity and Family Office Funds, Foundations & more.

Patients

A selected group of leading patient driven companies, non profits, foundations, associations and charities focused on the development of novel therapies for patients.

Who's Coming?

Venue

Bio-Neuroscience brings together an outstanding mix of leaders and decision-makers in CNS Neuroscience drug development.

Hotel Jakarta
Javakade 766, 1019 SH Amsterdam,
Netherlands

Bio-Neuroscience takes place at Hotel Jakarta, a sustainable modern hotel designed as a green oasis on the IJ river. The selection of the Hotel Jakarta Amsterdam as the new venue was made based on its central location, comfortable rooms and green atmosphere, and a setup which is well suited for the highly interactive but boutique interactive nature of Bio-Neuroscience, including improved plenary spaces, natural light, and increased networking space for business development and networking.

RESERVE YOUR HOTEL ROOM NOW.

The code BNEURO26 will provide participants a discount of 10% over the best available rate (at the moment of booking). This code is valid only for rooms booked in the period from the 20th of February until the 2nd of March.

Use the discount code BNEURO26 to book directly with the Hotel Jakarta link here.

HOTEL INFO

RESERVE HERE